Unlocking Systemic Treatment Solutions for Atopic Eczema and Psoriatic Arthritis: Recent Insights and Advances in Management Strategies

Webcast to detail Latest advances in Atopic Eczema and Related Skin Conditions

Utrecht, Netherlands – A complete webcast is scheduled for Wednesday, November 19th, from 8:00 PM to 9:30 PM, designed to offer crucial updates and practical guidance for healthcare professionals managing complex skin conditions. The event focuses on atopic eczema, prurigo nodularis, hand eczema, and associated comorbidities in both adult and pediatric populations.

Focus on Real-World Data

The webcast will highlight the application of real-world data to clinical practice. Experts will share recent findings concerning the use of biologicals and JAK inhibitors, strategies for recognizing and managing common side effects, and approaches to treatment switching. Discussions will also cover considerations for pregnancy and long-term management of prurigo nodularis.

specialized Tracks for Adults and Children

A key component of the webcast will be dedicated to the unique challenges of treating serious atopic eczema in children.Presenters will review long-term data related to drug survival, vaccination schedules, and tapering strategies. The potential for disease modification through biologicals and JAK inhibitors will also be assessed. Additionally, a choice matrix for pediatric atopic dermatitis will be examined.

Addressing Hand Eczema

The treatment of hand eczema,a notably challenging condition,will also receive focused attention. Recent real-world data on systemic treatments, including pediatric cases, will be presented. Experts will address the considerations for both atopic and non-atopic hand eczema.

Expert Speakers

The webcast will feature presentations from a distinguished panel of dermatologists.Prof. Dr. Marjolein de Bruin – Weller, from UMC Utrecht, Dr. Marie-louise Schuttelaar,from UMC Groningen,and Dr. Marlies de Graaf, also from UMC Utrecht, will share their expertise. Dr. Tom van ‘t Hek will serve as the moderator.

Professional Accreditation

Accreditation for this event is being requested from NVDV, NVK, VSR, and NAPA. This webcast is specifically targeted towards dermatologists, pediatricians, nursing specialists, and physician assistants. It will be offered free of charge.

Topic	Focus
Adult Atopic Eczema & Prurigo Nodularis	Biologicals, JAK inhibitors, side effect management, treatment switching, pregnancy considerations.
Children with Serious Atopic Eczema	Long-term data, drug survival, vaccinations, disease modification with biologicals/JAK inhibitors.
Hand Eczema	Systemic treatment options for both atopic and non-atopic forms, including pediatric cases.

Did You Know? According to the National Eczema Association, over 31.6 million Americans have some form of eczema. Source

Pro Tip: When managing atopic eczema, a proactive approach to identifying and avoiding triggers is crucial for long-term success.

Questions regarding the webcast can be directed to [email protected].

Understanding Atopic eczema: A Growing Concern

Atopic eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that affects millions worldwide. Its prevalence has been steadily increasing in recent decades, potentially due to a combination of genetic predisposition and environmental factors. Experts suggest that changes in lifestyle, increased exposure to allergens, and disruptions in the skin microbiome may all contribute to this rise. Addressing these factors through personalized treatment plans is increasingly critical.

The efficacy of biological therapies and JAK inhibitors in managing severe atopic eczema has been demonstrated in numerous clinical trials and is now being validated by real-world data. these targeted therapies offer a significant advancement over traditional treatments,providing more effective control of symptoms and improving quality of life for patients.

Frequently Asked questions About Atopic Eczema

What are your biggest challenges in managing atopic eczema in your practice? Share your thoughts in the comments below!

Don’t hesitate to share this critically importent details with your colleagues!

what are the key differences in the primary targets of TNF inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors in the treatment of Psoriatic Arthritis?

Understanding the Interplay: Atopic Eczema & Psoriatic Arthritis

Both atopic eczema (also known as atopic dermatitis) and psoriatic arthritis (PsA) are chronic inflammatory conditions, but their systemic treatment approaches are increasingly converging due to shared immunological pathways. While eczema primarily affects the skin,causing intense itch and inflammation,PsA impacts the joints,skin (often psoriasis),and entheses (where tendons and ligaments attach to bone). Recognizing this overlap is crucial for effective management. Systemic therapies – those affecting the whole body – are often necessary when topical treatments fail to provide adequate relief. Chronic inflammation, a hallmark of both diseases, drives the need for these more potent interventions.

The Role of Biologics in Atopic Eczema Management

Biologics have revolutionized eczema treatment, particularly for moderate-to-severe cases. these therapies target specific components of the immune system.

* Dupilumab (dupixent): This IL-4Rα inhibitor is a cornerstone of biologic therapy for atopic eczema. It blocks signaling pathways involved in type 2 inflammation, a key driver of eczema pathology. Clinical trials demonstrate significant improvements in eczema Area and Severity Index (EASI) scores and itch reduction.

* Tralokinumab-ldrm (Adbry): Another IL-13 inhibitor, tralokinumab offers an alternative for patients who may not respond optimally to dupilumab.

* Lebrikizumab-vzlr (Ebglyss): Targeting IL-13 as well, Lebrikizumab provides another option for patients with moderate-to-severe atopic dermatitis.

* Future Biologics: Research is ongoing into new biologics targeting different inflammatory pathways, offering hope for even more personalized treatment options.

Key Considerations for Biologic Use: patients should be screened for tuberculosis and other infections before initiating biologic therapy. Long-term safety monitoring is also essential. Eczema treatment is evolving rapidly, and staying informed about new options is vital.

Advancements in Systemic Therapies for Psoriatic Arthritis

PsA management has also seen significant progress with systemic therapies. The goal is to control inflammation, prevent joint damage, and improve quality of life.

* TNF Inhibitors: These were the first biologics approved for PsA and remain effective for many patients. Examples include etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab.

* IL-17 Inhibitors: secukinumab, ixekizumab, and brodalumab target IL-17, a cytokine heavily involved in PsA pathogenesis. They often demonstrate rapid and significant improvements in both skin and joint symptoms.

* IL-12/23 Inhibitors: Ustekinumab blocks both IL-12 and IL-23,offering another effective option for PsA.

* JAK inhibitors: Tofacitinib and upadacitinib are oral disease-modifying antirheumatic drugs (DMARDs) that inhibit Janus kinases, intracellular enzymes involved in inflammation. they provide an alternative for patients who prefer oral medication or have contraindications to biologics.

* Conventional systemic DMARDs: Methotrexate, sulfasalazine, and leflunomide remain valuable options, particularly for milder cases or in combination with biologics.

Bridging the Gap: Shared Treatment Strategies & Considerations

Increasingly, clinicians are recognizing the potential for overlapping treatment strategies.

* IL-17 Inhibitors: Show promise in both PsA and severe atopic eczema, particularly in patients with a Th17-dominant inflammatory profile.